{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"38"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"56"}],"units":"Participants"}],"description":"The number of patients who experienced grade 3+ adverse events for Phase II Analysis Group 2 for the initial treatment period is reported below.","groups":[{"description":"Protocol therapy will consist of 30 mg MLN0128 (TAK-228) administered weekly over a 4-week cycle.","id":"OG000","title":"Phase II - Analysis Group 2 MLN0128"},{"description":"Patients receive 400mg Pazopanib orally once daily over a 4-week cycle and titrated to tolerance (maximum 800mg) by the treating physician in the first intervention period/initial treatment period.","id":"OG001","title":"Phase II - Analysis Group 2 Pazopanib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Phase II Analysis Group 2 - Initial Treatment Period; This analysis excludes cancel patients (who never received treatment i.e. Withdrew before initiation of regimen )","reportingStatus":"POSTED","timeFrame":"Up to 4 months","title":"The Number of Patients Who Experienced Grade 3+ Adverse Events (Phase II Analysis Group 2 - Initial Treatment Period)","type":"SECONDARY","unitOfMeasure":"Participants"}